Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.

Publication ,  Journal Article
Hoffman, KB; Demakas, A; Erdman, CB; Dimbil, M; Doraiswamy, PM
Published in: BMJ
July 23, 2013

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMJ

DOI

EISSN

1756-1833

Publication Date

July 23, 2013

Volume

347

Start / End Page

f4656

Location

England

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Substance-Related Disorders
  • Product Surveillance, Postmarketing
  • Oseltamivir
  • Mental Disorders
  • Humans
  • General & Internal Medicine
  • Drug Approval
  • Data Mining
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hoffman, K. B., Demakas, A., Erdman, C. B., Dimbil, M., & Doraiswamy, P. M. (2013). Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ, 347, f4656. https://doi.org/10.1136/bmj.f4656
Hoffman, Keith B., Andrea Demakas, Colin B. Erdman, Mo Dimbil, and P Murali Doraiswamy. “Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.BMJ 347 (July 23, 2013): f4656. https://doi.org/10.1136/bmj.f4656.
Hoffman KB, Demakas A, Erdman CB, Dimbil M, Doraiswamy PM. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ. 2013 Jul 23;347:f4656.
Hoffman, Keith B., et al. “Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.BMJ, vol. 347, July 2013, p. f4656. Pubmed, doi:10.1136/bmj.f4656.
Hoffman KB, Demakas A, Erdman CB, Dimbil M, Doraiswamy PM. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ. 2013 Jul 23;347:f4656.

Published In

BMJ

DOI

EISSN

1756-1833

Publication Date

July 23, 2013

Volume

347

Start / End Page

f4656

Location

England

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Substance-Related Disorders
  • Product Surveillance, Postmarketing
  • Oseltamivir
  • Mental Disorders
  • Humans
  • General & Internal Medicine
  • Drug Approval
  • Data Mining